| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Vitamin K2 significantly inhibited proliferation of concanavarin A-stimulated peripheral blood mononuclear cells (PBMCs) derived from dialysis patients and healthy subjects. The vitamin K2 potencies were similar in these subjects. VK2 did not largely change the amounts of cytokines produced from activated PBMCs of both dialysis patients and healthy subjects. Percentage of regulatory T cells in PBMCs of dialysis patients, but not of healthy subjects, decreased by VK2 treatment.
Renal transplant recipients are received combination immunosuppressive therapy with steroids. Deviation in the VK2 pharmacological efficacies was small in PBMCs of both healthy subjects and dialysis patients. However, the steroid potencies on the activated PBMCs deviated largely. Therefore, we also developed and evaluated the PBMC suppressive efficacy of VK2 combined with other immunosuppressive drugs, aiming the application of this strategy to a new combination immunosuppressive therapy.
|
